Intervention not reported
Proportion of patients who had seizure remission in the last 9 months of the study · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who had seizure remission in the last 9… (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients with an adverse event · Patients between three and 10 years old with a diagnosis of BECTS
The intervention showed no clear difference in proportion of patients with an adverse event (moderate certainty).
1 finding from 1 review
Intervention not reported
Changes in cognitive function · Patients between three and 10 years old with a diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Proportion of patients who reported adverse events · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who reported adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients with a particular or serious adverse event: 1. Vertigo 2. Headache 3. Somnolence 4. Nausea/Vomiting 5. Tremor 6. Fatigue · Patients with a clinical and EEG diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Changes in cognitive function testing from baseline (96 weeks trial period) · Patients with a clinical and EEG diagnosis of BECTS
1 finding from 1 review
no estimate extracted
39 participants
Very low
Intervention not reported
Proportion of patients who are seizure free at 3 months · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who are seizure free at 3 months (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who are seizure free at 12 months · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who are seizure free at 12 months (very low certainty).
1 finding from 1 review
Serious adverse events · patients with initial ART
TDF showed no clear difference in serious adverse events compared with AZT (high certainty).
1 finding from 1 review
Virologic response · patients with initial ART
TDF showed no clear difference in virologic response compared with AZT (high certainty).
1 finding from 1 review
Adherence/tolerability/retention · patients with initial ART
TDF probably leads to higher adherence/tolerability/retention compared with AZT (moderate certainty).
1 finding from 1 review
Immunological response · patients with initial ART
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 1. Leaving the study early ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
Beta‐blockers showed no clear difference in global state: 2. Relapse ‐ short term compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 1. Death ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse effects: 1. Death ‐ medium term · patients with schizophrenia
1 finding from 1 review
Adverse effect: 2. General ‐ Short term · patients with schizophrenia
Beta‐blockers showed no clear difference in adverse effect: 2. General ‐ Short term compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 3. Specific ‐ cardiovascular ‐ short term · patients with schizophrenia
Beta‐blockers showed no clear difference in adverse effects: 3. Specific ‐ cardiovascular ‐ short term compared with placebo (low certainty).
1 finding from 1 review